Improving Practicality of Cell and Gene Therapies
Josh Ludwig, global director, commercial operations, ScaleReady, discussed making cell and gene therapy widely practical and viable for patients with cancer.
This content originally appeared on our sister site, Cancer Network.
CancerNetwork® spoke with Josh Ludwig, global director, commercial operations, ScaleReady, to learn more about the joint venture between Bio-Techne, Fresenius Kabi, and Wilson Wolf that launched in January 2021. The collaboration aims to make cell and gene therapy practical and viable for patients with cancer.
During the Deep Dive epsiode from the Medical World News® broadcast, Ludwig discussed how ScaleReady can support the entire industry, now and into the future, with a manufacturing platform that delivers a high throughput and efficient use of space. He also detailed G-Rex closed-system bioreactors, important processes for successful commercialization of cell and gene therapy, and future efforts utilizing ScaleReady.
This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences™ channels.
Considerations for Administering Hemoglobinopathy Gene Therapies From a Pharmacist’s Perspective
April 20th 2024Alexis Kuhn, PharmD, BCOP, a pediatric oncology pharmacist at Mayo Clinic, discussed the incorporation of the recently FDA-approved gene therapies for SCD and TDT into the work of pharmacists.
